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ABSTRACT Cross-species transmission of zoonotic coronaviruses (CoVs) can result in pandemic disease outbreaks. Middle East
respiratory syndrome CoV (MERS-CoV), identified in 2012, has caused 182 cases to date, with ~43%mortality, and no small ani-
mal model has been reported. MERS-CoV and Pipistrellus bat coronavirus (BtCoV) strain HKU5 of Betacoronavirus (-CoV)
subgroup 2c share>65% identity at the amino acid level in several regions, including nonstructural protein 5 (nsp5) and the
nucleocapsid (N) protein, which are significant drug and vaccine targets. BtCoV HKU5 has been described in silico but has not
been shown to replicate in culture, thus hampering drug and vaccine studies against subgroup 2c -CoVs. We report the syn-
thetic reconstruction and testing of BtCoVHKU5 containing the severe acute respiratory syndrome (SARS)-CoV spike (S) glyco-
protein ectodomain (BtCoVHKU5-SE). This virus replicates efficiently in cell culture and in young and agedmice, where the
virus targets airway and alveolar epithelial cells. Unlike some subgroup 2b SARS-CoV vaccines that elicit a strong eosinophilia
following challenge, we demonstrate that BtCoVHKU5 andMERS-CoVN-expressing Venezuelan equine encephalitis virus rep-
licon particle (VRP) vaccines do not cause extensive eosinophilia following BtCoVHKU5-SE challenge. Passage of BtCoV
HKU5-SE in youngmice resulted in enhanced virulence, causing 20%weight loss, diffuse alveolar damage, and hyaline mem-
brane formation in agedmice. Passaged virus was characterized by mutations in the nsp13, nsp14, open reading frame 5 (ORF5)
andM genes. Finally, we identified an inhibitor active against the nsp5 proteases of subgroup 2c -CoVs. Synthetic-genome plat-
forms capable of reconstituting emerging zoonotic viral pathogens or their phylogenetic relatives provide new strategies for
identifying broad-based therapeutics, evaluating vaccine outcomes, and studying viral pathogenesis.
IMPORTANCE The 2012 outbreak of MERS-CoV raises the specter of another global epidemic, similar to the 2003 SARS-CoV epi-
demic. MERS-CoV is related to BtCoVHKU5 in target regions that are essential for drug and vaccine testing. Because no small
animal model exists to evaluate MERS-CoV pathogenesis or to test vaccines, we constructed a recombinant BtCoVHKU5 that
expressed a region of the SARS-CoV spike (S) glycoprotein, thereby allowing the recombinant virus to grow in cell culture and in
mice. We show that this recombinant virus targets airway epithelial cells and causes disease in agedmice. We use this platform to
(i) identify a broad-spectrum antiviral that can potentially inhibit viruses closely related toMERS-CoV, (ii) demonstrate the ab-
sence of increased eosinophilic immune pathology for MERS-CoVN protein-based vaccines, and (iii) mouse adapt this virus to
identify viral genetic determinants of cross-species transmission and virulence. This study holds significance as a strategy to con-
trol newly emerging viruses.
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Rapid response strategies for understanding emerging viralpathogenesis, testing vaccines and therapeutics that can re-
strict epidemic spread, and preventing morbidity and mortality
are essential during the early phases of an epidemic. H5N1 and
H7N9 influenza viruses and coronaviruses (CoVs) are emerging
human pathogens that cause severe respiratory infections, often
culminating in acute respiratory distress syndrome (ARDS), an
end-stage lung disease associated with high mortality rates (1).
CoVs are enveloped viruses belonging to the orderNidovirales and
contain the largest known positive-sense RNA genome (~30 kb)
(2). CoVs can replicate efficiently in a wide range of mammalian
hosts and are divided into three major genera, Alphacoronavirus,
Betacoronavirus (-CoV), and Gammacoronavirus. Within these
genera, CoVs are further divided into subgroups 1a and b, 2a to d,
and 3 (3, 4). -CoVs include human CoVs HKU1 and OC43,
which cause mild to moderate respiratory disease, and the severe
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acute respiratory syndrome coronavirus (SARS-CoV), which
caused an epidemic in 2002 to 2003 that resulted in 10 to 50%
age-dependent mortality (5, 6).
More recently, another -CoV, called Middle East respiratory
syndrome coronavirus (MERS-CoV), emerged in theMiddle East
in April of 2012, causing pneumonia and ARDS, as well as renal
failure in some patients (7, 8). To date, MERS-CoV has spread to
eight countries and has been implicated in 182 cases and 79 re-
ported deaths, withmortality rates approaching 43%, especially in
elderly patients (9). MERS-CoV shares a close phylogenetic rela-
tionship with the Pipistrellus bat coronavirus (BtCoV) strain
HKU5 and Tylonycteris BtCoV strain HKU4; all three viruses are
classified in -CoV subgroup 2c (see Fig. S1A in the supplemental
material) (7, 10). Bats can serve as reservoirs for circulating
swarms of zoonotic viruses, and some are readily positioned to
directly cross the species barrier and infect human populations (3,
4). SARS-CoV is believed to have originated from closely related
bat predecessor strains similar to BtCoV HKU3, although the ex-
act precursor virus has not been identified (3, 4, 11). While the
zoonotic source of MERS-CoV remains unknown, recent reports
identified the presence of-CoVs with close amino acid similarity
to MERS-CoV in Nycteris and Pipistrellus bat species (12, 13).
Another study described the close similarity of MERS-CoV to Bt-
CoVHKU5; both of these homologous viruses share high degrees
of amino acid sequence similarity across important replicase pro-
tein targets, such as the 3C-like protease (3CLpro; also known as
nonstructural protein 5 [nsp5]) (82%), polymerase (92%), and
proofreading exonuclease (91%), as well as the nucleocapsid (N)
protein (68%) (7, 10). A recent finding suggests that most of these
proteins coevolve within subgroups of CoVs,making them attrac-
tive targets to test in models of closely related subgroups (14).
The lack of a small animal model for MERS-CoV has limited
the understanding of the pathogenesis of -CoVs belonging to
subgroup 2c, thereby hampering the development of vaccines and
therapeutics. BtCoV HKU5 shares a high degree of genetic se-
quence identity with MERS-CoV in the replicase targets and N
genes. Therefore, developing a small animalmodel will assist us to
identify viral determinants of pathogenesis and virulence, explore
the possibility of vaccine-induced eosinophilia for MERS-CoV
vaccines, and identify antivirals with broad activity against sub-
group 2c strains. Furthermore, to date, no subgroup 2c bat CoVs
have been cultured in vitro; the availability of infectious clones of
these viruses will help us to dissect common evolutionary rela-
tionships among pathogenic CoV strains.
We report the in vitro reconstruction and biological character-
ization, using reverse genetics and synthetic-genome design, of an
infectious clone of BtCoVHKU5 (icBtCoVHKU5) containing the
ectodomain from the SARS spike (S) protein (BtCoV HKU5-SE).
We show that BtCoVHKU5-SE replicated efficiently and demon-
strate that a small molecule inhibitor targeting 3CLpro effectively
inhibited BtCoV HKU5-SE and MERS-CoV replication in cell
culture. In addition, we report that BtCoVHKU5-SE replicated to
high titers in both young and aged mice but did not cause life-
threatening disease. Virus replication and disease were dependent
on the presence of the mouse angiotensin-converting enzyme 2
(ACE2) receptor, and immunohistochemistry staining demon-
strated the presence of viral antigen in epithelial cells lining the
small airways and alveoli. BtCoVHKU5-SE replication was inhib-
ited by SARS-CoV S protein-based vaccines but was not sensitive
to vaccines based on S proteins from subgroup 2c CoVs. Unlike
mice vaccinated with SARS-CoV N-expressing Venezuelan
equine encephalitis (VEE) virus replicon particles (VRP) (15), a
severe eosinophilic immune pathology was not observed follow-
ing BtCoV HKU5-SE challenge of animals vaccinated with VRP
expressing HKU5 N or MERS-CoV N, supporting the develop-
ment of killed and recombinant protein vaccines for MERS-CoV.
In vivo passage of BtCoV HKU5-SE in young mice resulted in
selection for a mouse-adapted strain (BtCoV HKU5-SEMA) that
replicated more efficiently and caused significant clinical disease
that progressed to interstitial pneumonia and diffuse alveolar
damage (DAD) in aged mice. Mutations in nsp13, nsp14, open
reading frame 5 (ORF5), and the M protein conferred increased
virulence in mice. Taken together, our results illustrate the utility
of synthetic-genomics-based platforms for rapidly generating a set
of related zoonotic viruses, identifying viral determinants of in-
creased virulence, assisting in the development of broadly active
drugs, and previewing potential vaccine-related complications,
which could provide invaluable directions for investigations dur-
ing the early phases of an epidemic.
RESULTS
Synthetic reconstruction of BtCoV HKU5. We have previously
described the synthetic reconstruction of a noncultivatable virus,
BtCoV HKU3 (16). As phylogenetic studies indicate that BtCoV
HKU5 is most closely related to MERS-CoV, we used published
sequence information to synthesize an infectious molecular clone
for BtCoV HKU5 (icBtCoV HKU5) (16, 17). The genome of the
virus was synthesized as six contiguous cDNA fragments, as
shown in Fig. 1A, and each subclonewas flanked by class II restric-
tion endonucleases that allow for directed assembly of a full-
length cDNA genome, which encodes a T7 start at the 5= end and
a poly(T) tract at the 3= end. Full-length RNAs were generated
using in vitro transcription of ligated cDNAs (16, 18). Upon elec-
troporation of Vero cells with the full-length RNA, no infectious
virus was recoverable, despite robust expression of BtCoV HKU5
N subgenomic mRNAs through 4 days postelectroporation (see
Fig. S1B in the supplemental material). Passage of cell culture
supernatants resulted in diminished viral subgenomic N mRNA
expression over time, and eventually, the recombinant virus went
extinct in culture (Fig. S1C).
Recovery of an icBtCoV HKU5 variant expressing the ecto-
domain of the SARS-CoV S protein. Previous studies from our
group and others demonstrated that substitution of the receptor
binding domain (RBD) from the SARS-CoV S glycoprotein en-
abled efficient in vivo replication of BtCoV HKU3 (16, 19). To
enable the recovery of BtCoV HKU5 in cell culture, we adopted a
similar strategy and assembled a recombinant chimeric BtCoV
HKU5 that encoded the S glycoprotein ectodomain (BtCoV
HKU5-SE) (Fig. 1A; yellow) from SARS-CoV (16, 19). A Y436H
substitution (change of Tyr to His at position 436) (Fig. 1A; aster-
isk), previously shown to enhance replication in mice (20), was
also included in the spike gene. BtCoV HKU5-SE chimeric virus
was recovered after electroporation of full-length transcripts into
Vero cells.
Molecular characterization of BtCoV HKU5-SE. In Vero
cells, BtCoV HKU5-SE replicated with kinetics similar to those of
MERS-CoV (MERS-CoV SA1, the Saudi Arabian isolate) and
SARS-CoV at earlier time points and achieved peak titers at 24 h
p.i. (Fig. 1B and C). Cytopathology was characterized by fusion of
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cells starting at 18 h p.i., and cell death was noted at ~36 h p.i.
BtCoV HKU5-SE was stable in cell culture, as indicated by real-
time PCR analysis of ORF1 andORF8 expression through passage
six (see Fig. S1D in the supplemental material). BtCoV HKU5-SE
replicated with kinetics similar to those of the MERS-CoV Eng-
land isolate (MERS-CoV Eng 1) (Fig. S2A). Interestingly, there
was a marked difference in virus replication (Fig. S2B) in high-
level-ACE2-expressing H2B Calu-3 cells (a lung epithelial cell
line), where BtCoVHKU5-SE replicated to lower titers than either
MERS-CoV isolates or SARS-CoV. Although speculative, this
growth difference is supported by low-level expression of N pro-
tein (Fig. S2C) at later time points and could reflect different sen-
sitivities to interferon in Calu-3 cells.
Efficient CoV replication and transcription involves the pro-
duction of a nested set of subgenomic mRNAs (2). Northern blot
analysis from Vero cells infected with BtCoV HKU5-SE revealed
eight subgenomic mRNAs (Fig. 2A). The predicted open reading
frames encoded by each of themRNAs are indicated in Table S1 in
the supplemental material.
Next, we characterized the expression of structural proteins in
cells infected with BtCoV HKU5-SE. Using antisera from mice
vaccinated with VRPs expressing BtCoV HKU5 N protein, we
demonstrated that BtCoVHKU5 infection of Vero cells produced
a discrete N protein band at the predicted molecular mass of
50 kDa in cell lysates (Fig. 2B). Polyclonal serum specific for
SARS-CoV S identified a 180-kDa S glycoprotein, along with a
smaller S1 subunit (90 kDa, fastermigrating band), in lysates from
infected Vero cells (Fig. 2C), consistent with the expression of the
SARS-CoV S ectodomain by the recombinant BtCoV HKU5-SE.
In contrast, the polyclonal serum raised against BtCoV HKU5 S
did not recognize the S protein (data not shown), supporting our
earlier observations that the major antibody epitopes for S pro-
teins are likely concentrated in theN terminus (21). TheNprotein
of BtCoVHKU5 shares ~68% sequence identity withMERS-CoV
and BtCoV HKU4 N proteins (7). To identify any possible cross-
reactivity with BtCoV HKU5-SE, we generated mouse polyclonal
sera using VRPs expressing the N proteins from BtCoV HKU4.2
and theMERS-CoV SA1 isolate and then demonstrated that these
sera recognized the BtCoVHKU5-SE N protein (Fig. S2D and E).
Taken together, these results demonstrate the presence of con-
served polyclonal antibody epitopes in subgroup 2c CoV N pro-
teins.
Protease inhibitors targetingMERS-CoV 3CLpro inhibit Bt-
CoVHKU5-SE in vitro. Small molecule inhibitors targeting 3CL-
pro efficiently block SARS-CoV replication (22, 23).With the 82%
sequence similarity between the nsp5 proteins of MERS-CoV and
BtCoVHKU5-SE, we are well positioned to identify broadly reac-
tive group 2c protease inhibitors, which is important because
there are significant functional and regulatory differences in the
nsp5 proteins of different subgroups (2a, 2b, and 2c) but strong
conservation of determinants within subgroups (14).
Therefore, we analyzed whether the small molecule inhibitor
FIG 1 Genome organization and replication of BtCoV HKU5-SE in Vero cells. (A) Schematic of the genome organization of BtCoV HKU5 (top) and the
recombinant virus in which the S protein was replaced with the ectodomain of SARS S glycoprotein (SE, yellow). The asterisk indicates the Y436H substitution.
The bottom panel represents cDNA fragments A to F encoding the genome, with the T7 start site, the poly(T) tract, and the BglI restriction sites flanking the
fragments. (B and C) BtCoV HKU5-SE replication in Vero cells compared with the replication of MERS-CoV Hu/SA-N1/2012 (MERS-CoV SA 1) (B) and
SARS-CoV (C). Vero cells were infected with BtCoV HKU5-SE, MERS-CoV, and SARS-CoV at the indicated MOIs. Supernatants were sampled in triplicate at
the times indicated, and titers determined on Vero cells by plaque assay. Error bars indicate standard deviations (SD).
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GRL-001 could inhibit the replication of
BtCoV HKU5-SE and MERS-CoV in cell
culture (23, 24). The enzymewas purified
using published methods (detailed in
Methods in Text S1 in the supplemental
material), resulting in high yield (28 mg/
liter) and purity, and inhibition assays
were conducted using a fluorimetric sub-
strate as described previously (22, 23).
GRL-001 was very potent in inhibiting
BtCoV HKU5 3CLpro activity, with an
inhibition constant (Ki) of 5.9 0.8 M
(mean  standard deviation). Vero cells
pretreated with 50 M concentrations of
inhibitors were infected with BtCoV
HKU5-SE orMERS-CoV at amultiplicity
of infection (MOI) of 0.1, and viral titers
were determined at 12, 24, and 36 h
postinfection (p.i.). Importantly, GRL-
001 completely blocked viral replication
at early time points, reduced BtCoV
HKU5-SE andMERS-CoV replication by
~100-fold at 24 h p.i. (Fig. 2D and E), and
reduced virus-induced cytopathology in
infected cells (Fig. 2F). Thus, GRL-001 is
a small molecule inhibitor that effectively
reduces the replication of multiple sub-
group 2c CoV strains.
BtCoV HKU5-SE replication in vivo.
To examine whether BtCoV HKU5-SE
replicates and causes disease in mice, we
intranasally infected young (~10-week-
old) and old (1-year-old) BALB/c mice
with 1  105 PFU of virus. BtCoV
HKU5-SE did not cause weight loss in
young animals, but aged BALB/cmice ex-
perienced ~10%weight loss by 4 days p.i.
(Fig. 3A). In the aged-mousemodel, clin-
ical signs of disease included lethargy,
ruffling of fur, andmildly labored breath-
ing patterns. More importantly, in both
young and agedmice, the virus replicated
to 106 and 104 PFU/g in the lungs at 2
and 4 days p.i. (Fig. 3B). Weight loss and
pathology changes were not noted in
mock-infected young and aged animals
(data not shown). Because the Y436H
substitution in the SARS-CoV S ectodo-
main enhances binding to the mouse
ACE2 receptor (20), we infected 1-year-
oldACE2/micewithBtCoVHKU5-SE
to assess whether ACE2 was required for
virus entry and disease. No weight loss or
virus replication was observed in
ACE2/ mice (Fig. 3A and B), clearly
identifying the requirement of mouse
ACE2 in BtCoV HKU5-SE entry, replica-
tion, and disease.
Although little if any pathology was
noted in young infected animals, aged
FIG 2 Subgenomic mRNA and protein expression in BtCoV HKU5-SE and the 3C-like protease
inhibitor study. (A) Northern blot showing subgenomic mRNA expression in BtCoV HKU5-SE-
infected cells. (B and C)Western blots showing expression of structural proteins N (B) and S (C) from
BtCoV HKU5-SE-infected cell lysates stained with polyclonal serum as indicated below the images. (D
and E)Viral titers from cells pretreatedwith 50MofGRL-001 and infectedwith BtCoVHKU5-SE (D)
and MERS-CoV (E) at an MOI of 0.1 PFU/ml. Drug treatment was continued after infection, and
virus-containing supernatants were sampled in triplicate. Error bars indicate SD. Asterisks indicate
statistical significance (P 0.05, Student t test). The structure of GRL-001 is shown to the right of panel
E. (F) Bright-field images of cells infected with BtCoV HKU5-SE or MERS-CoV at an MOI of 0.1,
showing strong cytopathic effects with no drug treatment (top, red arrows) and intact monolayers with
50 M GRL-001 treatment (bottom, red arrows) at 36 h p.i..
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mice developed more-severe airway disease, perivascular and
peribronchial cuffing, and pneumonia by 4 days p.i. The airway
disease (Fig. 3C and D, bottom) included denuded regions of the
airway epithelium, debris in the lumen of small airways, and peri-
bronchial cuffing with increased numbers of neutrophils and
monocytes. Perivascular cuffing was also evident, with large num-
bers of infiltrating neutrophils and monocytes. A few animals de-
veloped focal regions of severe pneumonia with accompanying
edema-filled alveoli, consistent with early acute DAD (Fig. 3D,
bottom). To identify cellular targets, immunohistochemistry with
polyclonal serum to HKU5 N protein was performed in lung sec-
tions of young and aged mice. As seen with SARS-CoV (25),
BtCoVHKU5-SE antigenswere abundant in airway epithelial cells
and in epithelial cells with features characteristic of type II pneu-
mocytes in the alveoli (Fig. 4). No staining was noted in mock-
infected lungs (Fig. 4, top and bottom, far right).
FIG 3 BtCoVHKU5-SE replication in BALB/cmice. (A)Weight loss in young (10-week-old) and aged (1-year-old) BALB/cmice and 1-year-old ACE2/mice
(BALB/c background) was measured after intranasal infection with 1 105 PFU of BtCoV HKU5-SE. (B) Viral replication in mouse lungs at 2 and 4 days p.i.
LOD, limit of detection. (C) Lung pathology from hematoxylin-and-eosin (H&E)-stained sections was blind scored for clinical disease features on a scale of 0 to
3 (1, mild; 3, severe). Error bars indicate SD. (D) RepresentativeH&E-stained sections of lungs from a young and an agedmouse harvested at 4 days p.i., showing
severe inflammatory infiltration in the aged mouse.
FIG 4 Viral antigen distribution in the lung. Immunohistochemistry was performed using anti-HKU5 N sera, and sections representing different regions of
lungs from young and agedmice at 2 days p.i. are shown. Stained sections of lungs frommock-infectedmice as controls are indicated on the extreme right in both
rows.
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S-expressing VRP vaccine studies in mice. Because BtCoV
HKU5-SE harbors the SARS-CoV S ectodomain, we evaluated
whether a SARS-CoV S-expressing VRP-based vaccine would
provide protection from virus-induced disease. Young and aged
mice were mock vaccinated (with VEE virus adjuvanted particles
[VAP]) or vaccinatedwithVRP expressing SARS-CoVS glycopro-
tein and then challenged with 105 PFU of BtCoV HKU5-SE. Vac-
cinated aged animals were completely protected from virus-
induced weight loss (Fig. 5A), and viral replication in the lungs
was significantly diminished (~4 log) by day 2 and cleared by
4 days p.i. (Fig. 5B). In contrast, viral replication was not detected
in young mice vaccinated with SARS-CoV S-expressing VRP (see
Fig. S3A in the supplemental material), demonstrating complete
protection. Consistent with this observation, the 50% plaque
reduction neutralization test (PRNT50) titers (against BtCoV
HKU5-SE) in vaccinated young and aged animals were 1:1,600
and 1:800, respectively (Fig. 5C). Furthermore, polyclonal sera
against HKU5 N and S proteins did not neutralize BtCoV
HKU5-SE (Fig. 5C). These results are consistent with the idea that
CoV S but not N proteins represent the principal determinants of
protective humoral immunity after high-titer challenge (15).
We then determined whether VRP vaccines expressing the S
proteins of other group 2c -CoVs (BtCoV HKU4 or HKU5 or
MERS-CoV) provided cross-protection against BtCoV HKU5-SE
replication in vivo. Analysis of viral replication at 2 days p.i. indi-
cated that none of these vaccines elicited cross-protection (see
Fig. S3A in the supplemental material). Our results are consistent
with a recent report showing the absence of cross-neutralization
using SARS-CoV S-specific antibodies against full-length MERS-
CoV S or its RBD (26).
Subgroup 2c N-based vaccines and immune pathology. Pre-
vious studies from our group and others have revealed immune-
mediated pathology in the lungs of mice immunized with N
protein-based subunit vaccines or doubly inactivated SARS-CoV
vaccines and subsequently challenged with homologous or heter-
ologous viruses (15, 27, 28). This immune-mediated pathology, as
also noted with inactivatedmeasles and respiratory syncytial virus
(RSV) vaccines, was characterized by the presence of high num-
bers of pulmonary eosinophils after challenge and potentially
poses a significant barrier in the development of vaccines against
other emerging CoV infections (29, 30). Importantly, the BtCoV
HKU5 N protein is 67% identical to MERS-CoV N and shares
cross-reactive epitopes. AsMERS-CoV does not replicate inmice,
the BtCoV HKU5-SE recombinant virus offers a unique heterol-
ogous challenge model for assessing whether group 2c N protein-
containing vaccines might elicit pulmonary immune pathology
characterized by increased eosinophilia upon challenge.
Youngmice weremock immunized (with VAP) or primed and
boosted with VRP expressing MERS-CoV N or BtCoV HKU5 N
and were subsequently challenged with BtCoV HKU5-SE. No ap-
preciable weight loss was observed in any of the groups (Fig. 5D),
and none of the vaccines provided protection from virus replica-
tion, as measured at 2 days p.i. (Fig. 5E). No significant increases
in the numbers of eosinophils in lungs at 4 days p.i. were noted in
mice immunized with either MERS-CoV N or BtCoV HKU5 N
compared to the levels of eosinophils in lungs of mock-
immunized animals (P  0.07, as determined by Tukey’s
multiple-comparison test) (Fig. 5F). Analysis of histopathology
sections also revealed no significant increases in the numbers of
eosinophils between the mock-immunized and N protein-
immunized groups (data not shown). No significant increases
were noted for monocytes, monocyte-derived dendritic cells, or
neutrophils between the N-vaccinated and mock-vaccinated
groups either (see Fig. S3B to D in the supplemental material).
FIG 5 Vaccine studies in mice. (A) Weight loss of aged mice (1 year old) vaccinated with SARS-CoV S or mock vaccinated prior to challenge with 105 PFU of
BtCoVHKU5-SE. (B)Virus titers in lungs at days 2 and 4 p.i. (C)Antiserum to SARS-CoVSprotein but not antiserum toHKU5SorNprotein neutralizes BtCoV
HKU5-SE in an in vitro PRNT50 assay. (D)Weight loss of youngmice eithermock vaccinated or vaccinated with VRP (virus replicon particles) expressingHKU5
N or MERS-CoV N and challenged with BtCoV HKU5-SE. (E) Virus titers in lungs of mice at 2 days p.i. (F) Flow cytometric analysis showing numbers of
eosinophils at 4 days p.i. in the lungs of mice either mock vaccinated or vaccinated with BtCoV HKU5 N orMERS-CoV N and then challenged with 105 PFU of
BtCoV HKU5-SE. Error bars indicate SD.
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However, there were significant increases in B cells (P  0.043)
andCD8Tcells (P 0.0002) between themock-immunized and
N vaccine-immunized animals (Fig. S3E and F). Consistent with
these findings, in a cell lysate-based enzyme-linked immunosor-
bent assay (ELISA), HKU5N andMERS-CoVN sera bound to the
appropriate recombinant proteins expressed by VRPs, indicating
induction of antigen-specific antibodies (Fig. S4). Taken together,
these results demonstrate that VRP-vectoredHKU5N- orMERS-
CoV N-based vaccines do not elicit significant eosinophilia after
homologous or heterologous challenge, supporting the develop-
ment of MERS-CoV vaccines.
Mouse adaptation of BtCoVHKU5-SE.Although the S glyco-
protein is a critical determinant for cross-species transmission,
additional mutations across the genome have been shown to con-
tribute to host switching and increased disease severity (20, 25).
To identify potential virulence alleles in BtCoV HKU5-SE, we se-
rially passaged BtCoV HKU5-SE in the lungs of 10-week-old
BALB/c mice over 2-day intervals. Virus from passage 9 (BtCoV
HKU5-SEMA [mouse adapted]) was plaque purified and used to
inoculate young (10-week-old) and aged (1-year-old) animals.
BtCoV HKU5-SE MA did not cause any significant weight loss in
young mice, but it caused 20% weight loss in aged mice
(Fig. 6A). The virus titers in lungs were significantly increased in
young and aged animals at days 2 and 4 p.i. (107 PFU/g and
~106 PFU/g, respectively) (Fig. 6B). Although young animals did
not exhibit any significant increases in pathology compared to
that inmice inoculatedwith nonadapted strains (Fig. 3D), all aged
animals developed acute interstitial pneumonia with fibrin depo-
sition and hyaline membrane formation (Fig. 6C). Genome se-
quencing in comparison to the sequence of the parent virus re-
vealed changes in the nsp13, nsp14,ORF5, andORF7 (M) genes as
a result of mouse adaptation (Fig. 7A and B, top). It was notewor-
thy that a frameshift mutation resulted in a truncated ORF5 poly-
protein (insertion of nucleotide G between 26,897 and 26,898 bp)
(Fig. 7B, top). Furthermore, virus was also detected in blood at
2 days p.i. (4  105 PFU/ml), but not in any other organs tested
(brain, liver, and spleen) (Fig. 7B, bottom).
DISCUSSION
A recent study by Anthony et al. estimates the presence of approx-
imately 320,000 different viruses circulating in mammalian zoo-
notic reservoirs that have the potential to cross the species barrier
and to emerge as new human pathogens (13, 31). Among corona-
viruses, high RNA recombination frequencies coupled with the
existence of interchangeable S domains suggest that some zoo-
notic strains are likely poised for cross-species transmission events
FIG 6 BtCoV HKU5-SE MA replication in young and aged BALB/c mice. (A) Weight loss curves of young (10-week-old) and aged (1-year-old) mice infected
intranasally with 1  105 PFU of BtCoV HKU5-SE MA through 4 days p.i. (B) Viral titers in lungs of mice at days 2 and 4 p.i. Error bars indicate SD. (C)
Representative H&E-stained sections of lungs from a young and an aged mouse harvested at 4 days p.i., showing severe inflammatory infiltration and hyaline
membrane formation (black arrow) in the aged mouse.
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into human populations (3). This study articulates a strategy that
would enable rapid development of therapeutics and targeted
evaluation of vaccines against future emerging zoonotic CoVs. A
biopreparedness platform that includes panels of recombinant
alpha-, beta-, and gammacoronaviruses for targeted therapeutic
and vaccine evaluations can provide a strategy for rapidly identi-
fying drugs with therapeutic potential against future emerging
zoonotic CoVs. Previous studies have shown that the feline and
murine S ectodomains and/or the S RBDs of the group 2b CoV S
glycoproteins are interchangeable (16, 19). As preemergent SARS-
like CoV group 2b strains with broad ACE2 receptor specificities
have recently been isolated from bats (11), it seems likely that
similar group 2c strains exist that have broad host range pheno-
types as well. In addition, the antigenic distances and minimal
cross-neutralization phenotypes seen across and within group 2b
and 2c strains (21) demonstrate an inherent vulnerability in cur-
rent vaccine and therapeutic design strategies, which focus on
single emerging isolates for control purposes. Rather, the syn-
thetic resurrection of the group 2bHKU3 strain Bat-SRBD (which
has the spike RBD from SARS-CoV) (16) and, here, the MERS-
CoV-like group 2c BtCoV HKU5-SE isolate provide crucial re-
agents for identifying broad-spectrum antivirals while addressing
targeted issues in vaccine design. BtCoV HKU5 and MERS-CoV
share high sequence identity across important replicase protein
targets (7, 14, 32). As most zoonotic viruses are difficult to culture
and usually exist as sequence signatures in repository databases,
the advent of synthetic biology has provided an approach for res-
urrecting representative strains from these highly heterogeneous
pools (16, 33, 34). Consequently, the potential risks versus bene-
fits of these experiments and the plans for containment of the
recombinant viruses were discussed in detail with the University
of North Carolina Institutional Biosafety Committee in advance
of these experiments.
Similar to our previous results with the subgroup 2b BtCoV
strain HKU3 (16), the recombinant BtCoV HKU5 replicated but
did not spread efficiently between cells, suggesting an entry block.
This observation could reflect a low level or lack of appropriate
receptor expression and/or other critical entry cofactors, such as
cathepsins or TMPSSR2 proteases (35). Using a chimeric BtCoV
HKU3 virus, we have previously demonstrated that the RBD of
SARS-CoV S protein alone is sufficient for binding to mouse
ACE2, enabling virus replication in mice (36). Inclusion of the
mouse-adapted Y436H substitution in S (37) enhanced BtCoV
HKU3 virus replication but not disease severity in aged-animal
FIG 7 BtCoV HKU5-SE MA genome sequence. (A) Schematics of BtCoV HKU5-SE, depicting all open reading frames (ORFs) (top) and the mouse-adapted
mutations as red stick-and-ball symbols at indicated spots in the genome (bottom). (B) Details of the mouse adaptations at the nucleotide and amino acid levels
(top), and analysis of viremia in BtCoV HKU5-SE MA-infected aged (1-year-old) BALB/c mice (bottom).
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models (16). In SARS-CoV recombinant viruses, S amino acid
substitutions are sufficient to produce severe disease in aged
BALB/c mouse models (20). In BtCoV HKU5, our attempts to
replace the putative HKU5 RBD with the SARS-CoV RBD were
unsuccessful,most likely reflecting the high antigenic distance and
structural incompatibilities that hinder genetic exchange of some
domains between subgroup 2b and 2c S glycoproteins. Supporting
earlier work with mouse hepatitis virus and feline coronavirus
(19), we introduced the SARS S glycoprotein ectodomain with the
Y436H substitution into the BtCoV HKU5 genome (BtCoV
HKU5-SE), and a recombinant chimeric virus was isolated that
was capable of productive infection in culture and in young and
aged BALB/c mice.
BtCoV HKU5-SE replicated efficiently in multiple cell types
and used mouse ACE2 for entry into mice. The virus replication
efficiency was reduced in interferon-competent Calu3 cells but
not in Vero cells, similar to the results for SARS-CoV, suggesting
the possibility of limited control by cell-intrinsic immune mech-
anisms as reported with SARS-CoV (38). Of interest, the ORF4b
genes of group 2c strains like HKU5 and MERS-CoV are closely
related and encode interferon antagonist activities, as detected
using reporter assays (39). Using reverse genetics, our group and
others have deleted these interferon antagonists fromMERS-CoV
(40, 41), with little to no effect on virus growth in vitro. The BtCoV
HKU5-SE molecular clone would enable the dissection of related
interferon antagonist activities in accessory ORFs of other group
2cCoVs, identifying common and unique pathways for regulating
innate immune responses in human cells. It is noteworthy that
ORF5 is not essential for the replication of either MERS-CoV or
BtCoV HKU5-SE.
In infected cells, eight subgenomic mRNAs were detected by
Northern blot assay, consistent with the predicted ORFs in Gen-
Bank and indicating successful replication and transcription.
Most CoVs, including BtCoV HKU5, MERS-CoV, and SARS
CoV, use a consensusACGAA transcriptional regulatory sequence
(TRS) start site, and the availability of a full panel of infectious
clones will allow us to engineer a recombination- and reversion-
proof genomeby rewiring theTRS sites, as previously described by
our group (42). The N and S glycoproteins were recognized by
their respective polyclonal sera. Cross-reactivity was noted be-
tween BtCoV HKU5-SE, BtCoV HKU4, and MERS-CoV N pro-
teins, demonstrating some conservation of antibody epitopes be-
tween the different strains. These data suggest that recombinantN
proteins andN-specific antisera can be used as diagnostic reagents
for serologic testing of human sera or direct detection of MERS-
CoV and other group 2c CoV antigens in tissues.
The BtCoV HKU5-SE virus contains an authentic set of sub-
group 2c replicase, accessory, and other structural proteins, pro-
viding a robust platform for evaluating the breadth of activity of
antiviral drugs against the group 2cCoVs. Among the Coronaviri-
dae, nsp5 (3CLpro) inhibitors have been shown to be successful in
inhibiting SARS-CoV replication in vitro (22, 23).Using biochem-
ical assays, the candidate drug GRL-001 inhibits MERS-CoV and
BtCoV HKU5-SE nsp5 protease activity (24) and reduces MERS-
CoV and BtCoV HKU5-SE replication by over 100-fold in vitro.
Although an intact monolayer was observed in drug-treated cells
at 36 h p.i., the virus titers were reduced only 10-fold. Similar
differences have been reported for coronavirus papainlike pro-
tease (PLP) inhibitors (43). The drug might be slowing down the
virus growth cycle and retarding the development of cytopathic
effect (CPE). In addition to blocking the effects of 3CLpro, GRL-
001 might interact with other host proteins activated during virus
infection and prevent cell death. Nevertheless, its broad therapeu-
tic action against distant group 2c CoVs supports the hypothesis
that GRL-001 is an effective inhibitor of 3CLpro activities in mul-
tiple subgroup 2c CoVs, providing a potential candidate drug for
future outbreaks. It is likely that GRL-001 will require modifica-
tions to improve its durability, biodistribution, and potency in
vivo.
BtCoVHKU5-SE caused disease in aged but not youngBALB/c
mice, leading to 10%weight loss by 4 days p.i. In contrast to other
coronaviruses, such as mouse hepatitis virus, which can still rep-
licate and produce disease in carcinoembryonic antigen-related
cell adhesion molecule 1-deficient (CEACAM1/) animals (44),
the replication and pathogenesis of BtCoV HKU5-SE was com-
pletely dependent upon the presence of themouse ACE2 receptor,
as the ACE2/mice clearly showed no weight loss or evidence of
virus replication. Furthermore, the presence of viral antigen in
small airway epithelial cells and in alveolar cells with morphology
like type II pneumocytes is characteristic of tropisms reported
during SARS-CoV infection inmice and primates (25, 45). Histo-
pathologic examination demonstrated interstitial pneumonia in
only a few aged animals, replicating phenotypes seen after infec-
tion with wild-type and mouse-adapted strains of SARS-CoV in
humans and mice (20, 25). The basis for age-related disease phe-
notypes following SARS-CoV infection has been linked to altera-
tion in prostaglandin expression in lungs that impairs dendritic
cell migration, resulting in a diminished T cell response (46). Fur-
ther studies are needed to evaluate the basis for the increased Bt-
CoV HKU5-SE pathogenesis in the aged-animal models.
Mouse adaptation of BtCoV HKU5-SE resulted in increased
viral replication and greater virulence in aged mice. Additionally,
animals developed interstitial pneumoniawith hyalinemembrane
formation. Mutations in nsp13, nsp14, ORF5, and ORF7 (M)
geneswere associatedwith increased virulence phenotypes in aged
mice. Interestingly, evolution in the nsp13, nsp14, and M genes
was also reported following SARS-CoV passage in mice (20, 25,
47) and humans during the expanding epidemic, which suggests
that they play critical roles in cross-species adaptation, replication,
and pathogenesis (48).
Importantly, the BtCoVHKU5-SE chimera was fully suscepti-
ble to a SARS-CoV S-based vaccine, and polyclonal serum raised
against SARS-CoV S completely neutralized the virus in vitro. The
difference in neutralization titers between young and aged ani-
mals likely reflects the gradient of immune response that occurs in
aged animals following emerging CoV infections (49). These data
demonstrate that the S glycoprotein retains key neutralization
epitopes critical for protective immunity (16). In contrast, none of
the VRPs expressing S proteins from BtCoV HKU4, BtCoV
HKU5, or MERS-CoV conferred protection in vivo, demonstrat-
ing the divergence between other group 2b and 2c CoV S proteins.
These findings argue that vaccine design for any novel emerging
CoV should involve S protein from the respective virus or a chi-
meric multivalent vaccine containing neutralizing epitopes from
the S proteins of different CoVs.
Previous studies fromour laboratory andothers have indicated
that animals immunized with vectored or inactivated SARS-CoV
N-containing vaccines develop an immune-mediated pathology
in the lungs following homologous or heterologous challenge,
reminiscent of RSV vaccine-mediated immune pathologies (27,
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28). This immune pathology is characterized by high numbers of
eosinophil infiltrates in the lungs postchallenge (28). Our results
demonstrate that VRP vaccines expressing MERS-CoV N did not
elicit an eosinophilic immune pathology following BtCoV
HKU5-SE challenge, as reported with inactivated SARS-CoV vac-
cines (27). In contrast to alum, which causes a Th2-skewed im-
mune response (27), VRP vaccines induce a robust Th1 immune
response and high neutralizing antibody titers (15, 27). Although
these studies should be interpreted with some caution, the effects
of inactivated MERS-CoV and BtCoV HKU5-SE vaccines in in-
duction of eosinophilia following challenge remain to be tested.
VRP vectors have been proven successful in human clinical trials
(50, 51), and VEE virus replicates successfully in several animal
species, including horses, goats, and sheep (52). Given the high
seroprevalence of MERS-CoV in camels and the potential role of
camels as intermediate reservoirs for human disease (53), the VRP
platform described here may be an effective MERS-CoV vaccine
candidate for use in camels and other reservoir species.
The development of infectious clones and recombinant viruses
from emerging zoonotic CoVs will expedite the rapid testing of
antivirals and vaccines in an outbreak situation. A limitation of
the current approach is that wild-type MERS-CoV and BtCoV
HKU5 do not replicate in mice. The recent demonstration of the
MERS-CoV S glycoprotein bound to its receptor may inspire
strategies for designing recombinant MERS-CoV strains that rep-
licate well in mice (54). Using BtCoV HKU5-SE, we illustrate the
utility of synthetic genomics and reverse genetic strategies for res-
urrecting emerging zoonotic viruses in vitro and validate our find-
ings using drugs and vaccines that can be readily applied in out-
break situations.
MATERIALS AND METHODS
Viruses, cells, and plaque assays. BtCoV HKU5-SE, MERS-CoV Hu/
England-N1/2012, and MERS-CoV Hu/SA-N1/2012 were cultured on
Vero 81 cells and grown inDulbeccomodified Eaglemedium (Gibco, CA)
with 5% Fetalclone II (Hyclone, South Logan, UT) and gentamicin-
kanamycin (Gibco, Carlsbad, CA). Growth curves in Vero and Calu-3
cells were performed as previously described (55). All virus cultivation
was performed in a biosafety level 3 (BSL3) laboratory with redundant
fans in biosafety cabinets (18, 20). All personnel wore powered air-
purifying respirators (3M Breathe Easy) and Tyvek suits, aprons, and
booties and were double gloved.
Generationof polyclonalmouse antisera, neutralization assays, and
Western and Northern blot analyses. Genes encoding the CoV S and N
proteins indicated above were synthesized by Bio Basic, Inc. (Ontario,
Canada) and were packaged into Venezuelan equine encephalitis (VEE)
virus replicon particles (VRPs) under BSL2 conditions using attenuated
VEE virus 3526 structural protein helpers. Following vaccination, mouse
polyclonal sera were generated in BALB/c mice, and neutralization assays
involving MERS-CoV isolates and SARS-CoV and using mouse antisera
were performed as described previously (49). For Western blotting, ly-
sates from cells infected with BtCoV HKU5-SE or MERS-CoV isolates
were prepared at 12 h p.i. as described previously (36). The blots were then
probed using the mouse polyclonal sera indicated above. Vero cells inoc-
ulated with BtCoV HKU5-SE were harvested at 12 h p.i. with TRizol
reagent (Invitrogen). Northern blot analysis to describe the genome- and
subgenome-length RNAs was performed using a probe for the N gene as
described previously (37).
Systematic assembly and recovery of full-length infectious clones of
BtCoVHKU5 variants. The BtCoVHKU5molecular clone was designed
based on a consensus sequence of BtCoVHKU5 isolates available in Gen-
Bank (nucleotide sequence accession number EF065512.1). The gene en-
coding the BtCoV HKU5 S protein (ORF2) was also replaced with the
full-length ectodomain of the SARS-CoV S protein (residues 1 to 1190)
using previously described strategies (16, 19). Themouse-adapted substi-
tutionY436H in the SARS-CoV spike protein (20, 25)was also included in
the chimeric S construct to promote replication in mice. This clone was
designated BtCoV HKU5-SE. The wild-type virus and chimeric BtCoV
HKU5 E fragments were synthesized by Bio Basic, Inc. (Ontario, Canada)
as six contiguous cDNAs. After assembly and in vitro transcription, re-
combinant virus was recovered on Vero cells through transfection of the
full-length transcripts, as previously described in detail (16, 18).
Biosafety statement. Synthetic reconstruction of BtCoV HKU5 and
BtCoV HKU5-SE was approved by the University of North Carolina IBC
(Institutional Biosafety Committee), which also reviewed possible dual
use research concerns before these experimentswere undertaken. The IBC
also examined the manuscript before submission.
BtCoVHKU5-SE replication and serial passage inmice. Young (10-
week-old) and aged (1-year-old) BALB/c mice purchased from Harlan
Labs were intranasally inoculated with a 50-l volume containing 1 105
PFU of BtCoV HKU5-SE virus. Infected animals were monitored for
weight loss, morbidity, and clinical signs of disease, and lung titers were
determined by plaque assay. Adaptation to mice was conferred by serial
passage in lungs of young BALB/c mice (10 weeks old) at 2-day intervals
p.i. as has been described in detail previously (25). Animal housing, care,
and experimental protocols were in accordance with University of North
Carolina Institutional Animal Care and Use Committee (IACUC) guide-
lines.
Immunohistochemistry. Lungs from mice infected with BtCoV
HKU5-SE were harvested at 2 and 4 days p.i. in 10% formalin and were
fixed for 7 days before removal from the BSL3. Paraffin-embedded tissues
(5M)were sectioned and stained with hematoxylin and eosin stain, and
lung sections were blind scored for pathological changes. Staining of viral
antigens was performed as described previously (25), using polyclonal
serum to the HKU5 N protein.
VRP-based S andNvaccination experiments.Young (~5- to 6-week-
old) and aged (~1-year-old)mice received, in the left footpad, a prime and
a boost of 105 PFU of different VRP-based S or N vaccines or Venezuelan
equine encephalitis virus adjuvanted particles (VAP) which expressed no
transgene as amock-infection control, with a 3-week interval between the
prime and the boost. At 3 weeks after the boost, the animals were moved
into the BSL3 facility and allowed to acclimate for 1 week. Then, they were
challengedwithBtCoVHKU5-SE. All young animalswere~13weeks, and
aged animals were 14 months old at the time of challenge.
Flow cytometry. Young BALB/c mice that were mock immunized
with 105 infectious units of VAP (expresses no transgene) or vaccinated
with VRP encoding BtCoV HKU5 N or MERS-CoV N were challenged
with 1  105 PFU of BtCoV HKU5-SE. The animals were weighed and
monitored for clinical symptoms daily. On day 4 p.i., mice were sacrificed
by isoflurane inhalation, and viable cell populations from the lungs were
prepared, stained with appropriate antibodies, and sorted using flow cy-
tometry as previously described in detail (27).
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